Determination of Triazolam by AccuTOF™ GC/Time-of-Flight Mass Spectrometry

Importance of the Topic

Triazolam is a short‐acting benzodiazepine commonly prescribed for sedation and insomnia. Its rapid clearance and potential impact on activities such as driving demand a highly sensitive and specific analytical method for accurate detection in biological fluids.

Objectives and Study Overview

The study evaluates the use of the JEOL AccuTOF GC time‐of‐flight mass spectrometer in negative ion chemical ionization mode to achieve accurate mass measurement and reliable quantitation of triazolam, using d4‐triazolam as an internal standard.

Methodology and Instrumentation

Sample preparation involved the addition of internal standard to aliquots of sample, solvent evaporation under nitrogen, and derivatization with BSA/TMCS prior to injection. An Agilent 6890N GC equipped with a DB5‐MS capillary column (30 m × 0.25 mm i.d. × 0.25 µm) operated in splitless mode was coupled to the AccuTOF GC/TOF MS. The method parameters included an oven program from 60 °C to 325 °C at 25 °C/min, helium carrier gas at 1 mL/min, methane reagent gas at 0.83 mL/min, and mass spectrometric settings optimized for NCI, with the ion source at 200 °C and detector at 2500 V.

Main Results and Discussion

The assay achieved a limit of detection of 5 ng/mL with a signal‐to‐noise ratio of 70 and mass accuracy error below 2 mmu. A linear calibration range from 5 ng/mL to 1000 ng/mL yielded R² = 0.9992. Precision tests showed %CV of 16.2% at 5 ng/mL and 3.2% at 10 ng/mL. The high sensitivity under NCI is attributed to triazolam’s two chlorine atoms, while BSA/TMCS derivatization improved peak shape.

Benefits and Practical Applications

The developed method provides unambiguous identification through accurate mass data, combined with high sensitivity and a straightforward sample preparation. It is suitable for routine screening and confirmatory analysis in clinical and forensic toxicology laboratories.

Future Trends and Potential Uses

Future work may focus on extending the method to biological matrices via optimized extraction and validation procedures, integrating high‐resolution time‐of‐flight detection for metabolite profiling, and adapting workflows for high‐throughput toxicological screening.

Conclusion

This is the first demonstration of GC/TOF MS with accurate mass measurement for triazolam determination. The method’s sensitivity, precision, and simplicity make it a promising approach for forensic and clinical applications, pending further validation in complex samples.

Reference

• 1. General information on triazolam half‐life: http://www.mentalhealth.com/drug/p30‐h01.html
• 2. Hold KM, Forensic Science International, 84 (1997), 201–209
• 3. Hold KM, Journal of Mass Spectrometry, 31 (1996), 1033–1038